Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-hodgkin's lymphoma or multiple myeloma

Pharmacotherapy

Volumn 32, Issue 7, 2012, Pages 596-603

  Lor, Kevin W ^a   Helmons, Pieter J ^a   Belew, Helen ^a,b   Lane, James R ^a   Ball, Edward D ^a,b  

^a UCSD MEDICAL CENTER   (United States)

^b Division of Blood and Marrow Transplantation   (United States)

Author keywords

Autologous stem cell transplantation; Mobilization; Multiple myeloma; Non Hodgkin's lymphoma; Plerixafor; Rescue

Indexed keywords

CYCLOPHOSPHAMIDE; PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; APHERESIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BIOACCUMULATION; CANCER COMBINATION CHEMOTHERAPY; CD34 SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LENGTH OF STAY; MALE; MULTIPLE MYELOMA; NAUSEA AND VOMITING; NEUTROPHIL; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; REVIEW; STEM CELL MOBILIZATION;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; ANTIGENS, CD34; BLOOD COMPONENT REMOVAL; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS;

EID: 84864617820     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2012.01096.x     Document Type: Review

References (15)

1. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009;28:4767-73.
2. DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009;23:5720-6.
3. Fowler CJ, Dunn A, Hayes-Lattin B, et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with GCSF and plerixafor (AMD3100): An institutional experience. Bone Marrow Transplant 2009;43:909-17.
4. Bashey A, Donohue M, Liu L, et al. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony- stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation. Transfusion 2007;11:2153-60.
5. Narayanasami U, Kanteti R, Morelli J, et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001;7:2059-64.
6. Sola C, Maroto P, Salazar R, et al. Bone marrow transplantation: Prognostic factors of peripheral blood stem cell mobilization with cyclophosphamide and filgrastim (r-metHuG-CSF): The CD34+ cell dose positively affects the time to hematopoietic recovery and supportive requirements after high-dose chemotherapy. Hematology 1999;3:195-209.
7. Jantunen E, Penttila K, Pyorala M, Mahlamaki E, Kuittinen T, Nousiainen T. Addition of plerixafor to a chemotherapy plus G-CSF mobilization in hard-to-mobilize patients. Bone Marrow Transplant 2011;46:308-9.
8. Allan DS, Keeney M, Howson-Jan K, et al. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;23:967-72.
9. Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheralblood stem cells. J Clin Oncol 1995;10:2547-55.
10. Dreger P, Kloss M, Petersen B, et al. Autologous progenitor cell transplantation: Prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995;10:3970-8.
11. Stiff PJ. Management strategies for the hard-to-mobilize patient. Bone Marrow Transplant 1999;23:S29-33.
12. Cyclophosphamide package insert. Available from http://patient. cancerconsultants.com/druginserts/Cyclophosphamide.pdf. Accessed on April 1, 2011.
13. Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib- containing regimens. Blood 2009;9:1729-35.
14. Shaughnessy P, Islas-Ohlmayer M, Murphy J, et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transplant 2011;17:124-32.
15. Lyman GH, Kuderer N. Epidemiology of febrile neutropenia. Support Cancer Ther 2003;1:23-35.